Exact claim · Version 1 · Reviewed July 31, 2026

“Melanotan II is basically the same thing as Scenesse or Vyleesi, just cheaper.”

A verdict on this wording and scope, not a universal grade for Melanotan II.

01 · Verdict

Misleading

Scenesse is a clinician-placed controlled-release implant of afamelanotide, a different molecule that binds predominantly to the melanocortin-1 receptor, approved for photosensitivity in erythropoietic protoporphyria. Vyleesi is bremelanotide, approved for a defined sexual-desire disorder in certain premenopausal women. Melanotan II is neither molecule and has no approval, no label, no established dose, and no verified vial content.

Evidence basis: Regulatory or product record
Scope: Both versions of the confusion: melanotan marketed as equivalent to the approved Scenesse implant, and melanotan II marketed as a cheaper route to the approved bremelanotide effect.
Category: Product equivalence

02 · Primary record

Check the attached evidence

01SCENESSE (afamelanotide) prescribing informationDailyMed · U.S. National Library of Medicine · Drug label · 2026
Supports the corrective verdict 02VYLEESI (bremelanotide) prescribing informationDailyMed · U.S. National Library of Medicine · Drug label · 2026
Supports the corrective verdict 03Scenesse European public assessment reportEuropean Medicines Agency · Regulatory · 2014
Supports the corrective verdict 04Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the internetPubMed · Drug Testing and Analysis · Reference · 2015
Supports the corrective verdict

Editorial review: Internal editorial review recorded
Responsible editor: Anthony Treviso · Founder and responsible editor
Clinical-review boundary: Not independently medically reviewed.